Novo Nordisk's Ozempic 2 mg was associated with a lower risk of serious cardiovascular adverse events in adults with type 2 diabetes, and the risk was lower than switching to Mounjaro, according to a real-world study presented at the European Association for the Study of Diabetes.

Novo Nordisk's Ozempic 2 mg was associated with a lower risk of serious cardiovascular adverse events in adults with type 2 diabetes, and the risk was lower than switching to Mounjaro, according to a real-world study presented at the European Association for the Study of Diabetes.